Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 08, 2025 08:30 ET | Source: CytoDyn Inc.

CytoDyn to Showcase PD-L1 Upregulation and Improved Survival in Metastatic Triple Negative Breast Cancer at the San Antonio Breast Cancer Symposium

Leronlimab treatment is associated with upregulation of PD-L1 in circulating tumor cells and cancer-associated macrophage-like cells Remarkably longer survival was observed in patients treated with...
December 01, 2025 08:30 ET | Source: CytoDyn Inc.

CytoDyn Announces Resolution of Class Action Lawsuit

VANCOUVER, Washington, Dec. 01, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized...
November 24, 2025 08:30 ET | Source: CytoDyn Inc.

CytoDyn to Present Prolonged Survival Data on Leronlimab in Metastatic Triple-Negative Breast Cancer at the San Antonio Breast Cancer Symposium

Company to deliver a poster presentation on clinical data demonstrating sustained remissionfollowing immune checkpoint inhibitor therapy with or after leronlimab treatmentin patients with metastatic...
November 03, 2025 08:30 ET | Source: CytoDyn Inc.

CytoDyn Secures $30 Million Commitment from Yorkville Advisors

VANCOUVER, Washington, Nov. 03, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized...
October 09, 2025 08:30 ET | Source: CytoDyn Inc.

CytoDyn to Present at the LD Micro Main Event XIX Investor Conference

CFO Robert E. Hoffman to deliver company presentation on October 21, 2025 VANCOUVER, Washington, Oct. 09, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a...
September 30, 2025 08:30 ET | Source: CytoDyn Inc.

September 2025 Letter to Shareholders

VANCOUVER, Washington, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Dear Shareholders, As this pivotal year continues to take shape for CytoDyn Inc. (“CytoDyn” or the “Company”), I am pleased to share the...
September 25, 2025 08:30 ET | Source: CytoDyn Inc.

CytoDyn to Present on Leronlimab Induction of PD-L1 and Immune Checkpoint Inhibitor Responses in Metastatic Triple-Negative Breast Cancer at the AACR Special Conference: Mechanisms of Cancer Immunity and Cancer-related Autoimmunity

Company to deliver oral and poster presentations for data on leronlimab’s action on PD-L1 expression and patient survival in triple-negative breast cancer VANCOUVER, Washington, Sept. 25, 2025 ...
September 16, 2025 08:30 ET | Source: CytoDyn Inc.

CytoDyn to Present at the AACR Special Conference: Mechanisms of Cancer Immunity and Cancer-related Autoimmunity

VANCOUVER, Washington, Sept. 16, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized...
September 04, 2025 08:30 ET | Source: CytoDyn Inc.

CytoDyn Updates Time of Presentation at the H.C. Wainwright 27th Annual Global Investment Conference

VANCOUVER, Washington, Sept. 04, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage biotechnology company advancing leronlimab, a first-in-class...
August 28, 2025 08:30 ET | Source: CytoDyn Inc.

CytoDyn to Present at the H.C. Wainwright 27th Annual Global Investment Conference

VANCOUVER, Washington, Aug. 28, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage biotechnology company advancing leronlimab, a first-in-class...